NICE Technology Appraisal Guidance No.286; Loxapine inhalation for the treatment of acute agitation and disturbed behaviours associated with schizophrenia or bipolar disorder

Proposal to update the existing guidance within a Clinical Guideline

NICE is currently unable to recommend the use of loxapine inhalation for the treatment of acute agitation and disturbed behaviours associated with schizophrenia or bipolar disorder, as a submission was not received from the manufacturer during the development of the appraisal.

NICE is currently developing an update of the clinical guideline for violence and aggression (CG25).The clinical guideline will be able to make recommendations on the use of loxapine for the treatment of acute agitation and disturbed behaviours associated with schizophrenia or bipolar disorder, meaning the termination advice in TA286 can be superseded.

Consequently, the decision has been made to allow the clinical guideline to include the use of loxapine, meaning that the termination advice in TA286 will be withdrawn at the point which the clinical guideline is published.  The anticipated publication date is April 2015.

February 2014